Pediatric COVID-19 Update: Cardiovascular Implications and The Use of Remdesivir

Visit the CE Central event page to enroll in the eLearning course “Pediatric COVID-19 Update: Cardiovascular Implications and The Use of Remdesivir.” - External Site

Login to your CE Central account is required to enroll and access online materials. Learn how to create an account in CE Central. - PDF

Topics

Cardiovascular Implications of COVID-19 in the Pediatric Patient

OBJECTIVES: Describe cardiac manifestations of COVID-19 infection and MIS-C. Discuss follow-up considerations and long-term concerns that may result from MIS-C. Discuss current recommendations regarding return to sports after COVID-19 infection.

The Use of Remdesivir in Children

OBJECTIVES: To discuss acute COVID-19 in Pediatric populations and its manifestations in the context of a case-based presentation. To discuss the context of emergency-use authorization (EUA) and clinical screening for Remdesivir use. To discuss the potential toxicities and exclusion criteria for Remdesivir use.

Presenters:

• David Weiland, MD, Assistant Professor, Pediatric Cardiology, UMMC
• Roberto Santos, MD, Professor, Pediatric Infectious Disease; Microbiology, UMMC

The planners and speakers for this eLearning have no relevant financial relationships to disclose. There is no cost to participate in this eLearning activity.

AMA: The University of Mississippi School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Mississippi School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.